Signos Secures $20M To Scale CGM & Behavioral Coaching in the GLP-1 Era

A cross-industry trio of Google Ventures, Dexcom and Blue Cross Blue Shield of Alabama is behind Signos’ latest round as the company targets the GLP-1 rebound many users experience

Weight-loss medications such as Ozempic and Wegovy have led many users to improved A1Cs and boosted membership rolls at their local gyms. They may now be about to boost the continuous glucose monitoring wearable space too.

Signos, maker of an FDA-cleared, over-the-counter wearable that monitors glucose, has raised $20 million to accelerate growth, with backing from Google Ventures, Dexcom and Blue Cross Blue Shield of Alabama via 450 Ventures.

It builds on a previous $20 million Series B funding round in 2023, led by Cheyenne Ventures and Google Ventures with support from Dexcom Ventures and Samsung Next.

The company, which reports it has grown 10-fold over the past six months and sees increased consumer demand for weight management options, is now building an AI coaching layer. It will interpret glucose data in real time, delivering metabolic guidance, gamified tools and “Weight Loss Signal” analytics.

Investor interest, particularly that of a health insurance company, signals what CGMs could mean for GLP-1 users. One in eight U.S. adults has taken a GLP-1, per KFF, and maintenance is still the category’s unsolved problem for many.

Weight-loss medications blunt hunger, but they don’t teach users how to eat once the prescription ends. Signos says its CGM addresses that by showing users in real time which foods spike their glucose, which meals keep them in range and how small adjustments add up.

Much like how wearables from Oura and Whoop can be monitoring tools that prompt better choices, Signos’ system translates glucose biosensing data into actionable insights that can guide what users eat, building what the company calls metabolic self-knowledge.

“The weight management category is being completely reimagined right now, and the approaches that will endure are the ones that combine the best of medication with the best of personalized data,” Signos CEO and founder Sharam Fouladgar-Mercer said.

The CGM will also be found on Dexcom’s consumer website, Stelo.com.